• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

CDEX Inc. Announces Expansion of Its Medication Signature Library Used By Its ValiMed(TM) Product Line

Posted on: Thursday, 26 July 2007, 09:20 CDT

CDEX Inc. (OTCBB: CEXI) announces the addition of 16 new signatures to its ValiMed(TM) Medication Signature Library. The ValiMed System, developed by CDEX and distributed by Baxa Corporation, provides hospital clinicians with a quick, cost-effective, and simple tool to further ensure medication safety by verifying that medications are compounded correctly.

Using Enhanced Photoemission Spectroscopy, ValiMed quickly validates high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication's spectroscopic signature to the expected signature from the Medication Signature Library and returns an easy to understand "validated" or "not validated" result, requiring no user interpretation.

"We are working with our new and existing customers to prioritize the compounded medications that they need as we schedule new signature development," said Carlos Alverez, CDEX's Manager of Production and Technical Support. "When our team develops a ValiMed signature, we test over 400 separate samples of the medication and by computer do over one million individual mathematical comparisons. Then the potential signature is scrubbed though a number of practical and medical gates before it is placed in the CDEX Library for use by our clients. We know that the accuracy of each signature is important to our clients and the patients that they serve -- and it is critical that we get it right."

"The addition of these 16 signatures brings our ValiMed Signature Library to 88 signatures and puts us ahead of schedule to meet our commitment of having an available library of 150 medication signatures for our customer's use by the end of the year," said Stuart Poteet, Manager of Marketing and Client Support. Being able to surpass the established schedule for the development of the medication signatures, while we continue to schedule the backlog for the installation of ValiMed systems purchased by both new and repeat customers, reaffirms our commitment to our customers and to improving patient safety."

For a complete list of the ValiMed Medication Signature Library see www.ValiMed.com or www.CDEX-Inc.com.

About CDEX Inc.

CDEX Inc. is a technology development company with a current focus on developing and marketing innovative products using chemical detection and validation technologies. At present, CDEX is devoting its resources to two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com and www.valimed.com or contact CDEX Inc. at 888.701.CDEX (2339) or cdexmanagement@cdex-inc.com.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Key products include Rapid-Fill(TM) Automated Syringe Fillers, Exacta-Med(R) Oral Dispensers, MicroFuse(R) Syringe Infusers, Repeater(TM) Pharmacy Pumps, and Exacta-Mix(TM) and MicroMacro(TM) Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Finland, France, Germany, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide. Further information is available at www.baxa.com.

Any statements made in this press release, which contain information that is not historical, are essentially forward-looking. Many forward-looking statements can be identified by the use of words such as "expects,""plans,""may,""anticipates,""believes,""should,""intends,""estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks are detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.

 Contact: CDEX Inc. 888.701.CDEX (2339) cdexmanagement@cdex-inc.com  Market News First Angela Junell 214-461-3411 ajunell@MN1.com

SOURCE: CDEX, Inc.

Source: MARKET WIRE

More News in this Category